Source: Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jeongha Mok, Hyungseok Kang, Won-Jung Koh, Byung Woo Jhun, Jae-Joon Yim, Nakwon Kwak, Taehoon Lee, Bohyoung Kang, Doosoo Jeon. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea. Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019

Member's Comments

No comment yet.

Related content which might interest you: Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa Source: Eur Respir J, 51 (5) 1800544; 10.1183/13993003.00544-2018 Year: 2018 Treatment outcome in patients with MDR-TB treated with bedaquiline containing regimens, Republic of Moldova Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Improvement of treatment adherence and success in homeless patients with tuberculosis in Iasi, Romania Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 Smoking and treatments among asthma patients in South Korea Source: Annual Congress 2011 - Smoking-related diseases and smoking cessation Year: 2011 A follow up Study of TB patients put on DOTS from South India Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 The effectiveness of the treatment of patients with TB in the condition adapted DOTS-strategy in Ukraine Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Outcomes of individualized treatment for MDR TB in Iran Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007 Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 An integrated MDR-TB management programme results in favourable outcomes in northern Taiwan Source: Eur Respir J 2015; 45: 272-275 Year: 2015 A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 The treatment outcomes of isoniazid resistant tuberculosis: Multicenter and retrospective study in South Korea Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013 Efficacy and tolerability of linezolid in the treatment of MDR-TB cases: a TBNET study in Germany and Italy Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Death rates in patients during and after MDR-TB treatment in a semi rural area of South Africa Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011